NovaBay Pharmaceuticals, Inc. (NBY) Stock Price

NBYStock

$1.27−87.96%52W

Market Cap—

P/E—

PEG Ratio—

Div yield0.00%

Beta1.21

NBY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.71%

Price vs S&P 500 (4W)21.14%

VGM Score38.81

Indicated Dividend Yield (Annual)0.00%

P/CF (Annual)19.21x

Book Value / Share (Quarterly)$1.36

P/TBV (Annual)0.40x

Revenue Growth (3Y)5.12%

Cash Flow / Share (Quarterly)$0.11

Price vs S&P 500 (YTD)-108.91%

Gross Margin (TTM)54.56%

Net Profit Margin (TTM)-88.52%

EPS (TTM)$-4.09

10-Day Avg Trading Volume0.82M

EPS Excl Extra (TTM)$-4.09

Revenue Growth (5Y)8.19%

EPS (Annual)$-2.13

Dividend / Share (Annual)$0.37

ROI (Annual)-216.58%

Gross Margin (Annual)66.26%

Net Profit Margin (5Y Avg)-78.66%

Cash / Share (Quarterly)$0.32

Revenue Growth QoQ (YoY)-78.66%

ROA (Last FY)-211.01%

Revenue Growth TTM (YoY)-74.73%

EBITD / Share (TTM)$-4.01

ROE (5Y Avg)-306.84%

Operating Margin (TTM)-89.93%

Cash Flow / Share (Annual)$0.11

P/B Ratio31.77x

P/B Ratio (Quarterly)4.70x

Net Income / Employee (Annual)$-515,900

EV / Revenue (TTM)15.56x

Net Interest Coverage (TTM)-399.56x

ROA (TTM)-460.21%

EV / EBITDA (TTM)49.47x

EPS Incl Extra (Annual)$-2.13

Current Ratio (Annual)7.60x

Quick Ratio (Quarterly)7.33x

3-Month Avg Trading Volume0.91M

52-Week Price Return-87.96%

EV / Free Cash Flow (Annual)16.29x

Revenue / Employee (TTM)$202,100

Tangible BV / Share (Quarterly)$10.33

P/S Ratio (Annual)5.31x

Asset Turnover (Annual)2.86x

52-Week High$99.75

Operating Margin (5Y Avg)-76.31%

EPS Excl Extra (Annual)$-2.13

CapEx CAGR (5Y)-21.40%

Tangible BV CAGR (5Y)25.03%

26-Week Price Return-0.78%

Quick Ratio (Annual)7.33x

13-Week Price Return11.40%

Total Debt / Equity (Annual)0.34x

Current Ratio (Quarterly)7.60x

Enterprise Value$44.03M

Revenue / Share Growth (5Y)-23.01%

Asset Turnover (TTM)0.82x

Book Value / Share Growth (5Y)38.59%

Revenue / Employee (Annual)$698,600

Inventory Turnover (Annual)1.81x

Pretax Margin (Annual)-73.71%

Cash / Share (Annual)$0.32

3-Month Return Std Dev125.17%

Gross Margin (5Y Avg)60.92%

Net Income / Employee (TTM)$-2,129,400

ROE (Last FY)-290.89%

Net Interest Coverage (Annual)-152.45x

EPS Basic Excl Extra (Annual)$-2.13

P/FCF (TTM)5.58x

Receivables Turnover (TTM)5.28x

EV / Free Cash Flow (TTM)16.29x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-4.09

Receivables Turnover (Annual)17.04x

ROI (TTM)-104.74%

P/S Ratio (TTM)18.35x

Pretax Margin (5Y Avg)-78.61%

Revenue / Share (Annual)$2.88

Tangible BV / Share (Annual)$51.64

Price vs S&P 500 (52W)-103.94%

Year-to-Date Return-95.50%

5-Day Price Return51.91%

EPS Normalized (Annual)$-2.13

ROA (5Y Avg)-95.83%

Net Profit Margin (Annual)-73.85%

Month-to-Date Return34.36%

Cash Flow / Share (TTM)$-5.24

EBITD / Share (Annual)$-2.11

Operating Margin (Annual)-59.83%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)19.21x

ROI (5Y Avg)-146.64%

LT Debt / Equity (Quarterly)1.65x

EPS Basic Excl Extra (TTM)$-4.09

P/TBV (Quarterly)0.40x

P/B Ratio (Annual)0.40x

Inventory Turnover (TTM)1.81x

Pretax Margin (TTM)-93.85%

Book Value / Share (Annual)$51.64

Price vs S&P 500 (13W)7.51%

Beta1.21x

P/FCF (Annual)19.21x

Revenue / Share (TTM)$2.41

ROE (TTM)-109.37%

52-Week Low$0.78

vGradeD

gGradeD

mGradeC

vgmGradeD

NBY Analyst Recommendations

Jun 2025

Jul 2025

Aug 2025

Oct 2025

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NBYNovaBay Pharmaceuticals, Inc.	D	D	C	18.3x	-74.7%	54.6%	—	$1.27
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals develops and commercializes clinically-proven eyecare, wound care, and skin care products. Its flagship product, Avenova Antimicrobial Lid and Lash Solution, is marketed directly to consumers online and prescribed by eyecare professionals for blepharitis and dry-eye disease. The product features broad-spectrum antimicrobial properties to remove microorganisms and debris from the eye area.